Friday, 29 March 2024


Pfizer's Herceptin biosimilar approved in Europe

31 July 2018 | News

Trazimera is the third biosimilar version of Roche's Herceptin in Europe.

Singapore – The European Commission approves Pfizer's TRAZIMERA, a biosimilar of Roche's cancer med Herceptin (trastuzumab).

TRAZIMERA, a potential biosimilar to Herceptin (trastuzumab), targets the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

The advisory group CHMP adopted a positive opinion backing approval in May.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account